Tepezza
Tepezza ingredients
| Active ingredient | Strength |
|---|---|
| Teprotumumab | 500 mg/1 |
What Tepezza is used for
The FDA lists the approved uses on the official label (below). In the EU, teprotumumab is approved as Tepezza for:
Treatment of moderate to severe thyroid eye disease (TED).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Tepezza
- Generic name
- Teprotumumab
- Made by
- Horizon Therapeutics USA, Inc.
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- Drug class
- Insulin-like Growth Factor-1 Receptor Inhibitor
- FDA approval
- Biologic licence (BLA) BLA761143
- On the US market since
- 2020
Official information
- MedlinePlus drug information (search for Teprotumumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Tepezza?
Tepezza (Teprotumumab) is a specialist medicine made by Horizon Therapeutics USA, Inc., approved by the US FDA.
What are the ingredients of Tepezza?
Tepezza contains Teprotumumab (500 mg/1).
Is Tepezza approved in Europe?
The same active substance is approved in the EU as Tepezza.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA